astuprotimut-R

Astuprotimut-R is a recombinant therapeutic cancer vaccine designed to stimulate the immune system against tumor cells expressing the melanoma antigen A3 (MAGE-A3). It consists of a recombinant form of human melanoma antigen A3 combined with a proprietary adjuvant, aiming to induce an immune response that targets and destroys cancer cells. The drug was developed for use in various cancers, including non-small cell lung cancer, malignant melanoma, bladder cancer, and multiple myeloma. Its mechanism involves immunostimulation and modulation of the tumor-associated antigen MAGE-A3. Astuprotimut-R was originally developed by GlaxoSmithKline in collaboration with Ludwig Institute for Cancer Research[1][2][5].

Brand names

Zastumotide

Other names

zastumotideD1/3 MAGE-3 fusion proteinD1/3 MAGE-3 fusion protein SB MAGE-3D1/3 MAGE–3 HisD1/3 MAGE–3 His fusion proteinSB MAGE–3SID 534984SID534984SID-534984MAGE-A3 antigen specific cancer immunotherapeuticMAGE-A-3 antigen specific cancer immunotherapeuticMAGE-A 3 antigen specific cancer immunotherapeuticMAGE-A3 ASCIMAGE-A-3 ASCIMAGE-A 3 ASCI